BPC-157 vs Fenbendazole for dogs
The short answer
These are rarely genuine alternatives — they answer different questions — but they are often encountered together by owners researching a dog with cancer. BPC-157 is a regenerative peptide with no established anticancer activity; its relevance in an oncology patient is supportive, around surgical recovery or gastrointestinal side effects of treatment. Fenbendazole is a repurposed antiparasitic being investigated for direct antitumour activity. If the question is what might act against a tumour, BPC-157 is not that compound. If the question is how to support a dog through treatment, fenbendazole is not that compound either.
Side by side
| BPC-157 | Fenbendazole | |
|---|---|---|
| Evidence grade | Emerging evidence | Emerging evidence |
| Intent | Tissue repair and recovery support | Investigational antitumour activity |
| Route | Injectable | Oral |
| Monitoring | Routine | Monthly CBC for bone marrow suppression, liver panel |
| Interaction caution | None established | Must not be combined with vincristine or paclitaxel |
| Full profile | BPC-157 for dogs | Fenbendazole for dogs |
Safety at a glance
BPC-157
BPC-157 has the most reassuring safety record of any compound on this site as it applies to dogs. A dedicated preclinical safety evaluation identified no lethal dose, no genotoxicity, and no teratogenicity, and the canine pharmacokinetic study reported good tolerance across seven days of repeated dosing at 30 mcg/kg — several times a typical clinical dose. The meaningful caveat is duration rather than dose: long-term continuous use in dogs has not been studied.
Is BPC-157 safe for dogs? →Fenbendazole
Fenbendazole at its labelled three-day deworming dose is one of the safest drugs in veterinary medicine, which is exactly why the extended oncology schedules get discussed so casually — and why that framing is misleading. Pancytopenia has been documented in dogs on extended daily dosing, and hepatic injury has been reported in human self-administration cases. The three-on / four-off cycling and the monthly CBC exist specifically to manage that. It also must not be combined with vincristine or paclitaxel.
Is Fenbendazole safe for dogs? →Common questions
Which is better for dogs, BPC-157 or Fenbendazole?+
These are rarely genuine alternatives — they answer different questions — but they are often encountered together by owners researching a dog with cancer. BPC-157 is a regenerative peptide with no established anticancer activity; its relevance in an oncology patient is supportive, around surgical recovery or gastrointestinal side effects of treatment. Fenbendazole is a repurposed antiparasitic being investigated for direct antitumour activity. If the question is what might act against a tumour, BPC-157 is not that compound. If the question is how to support a dog through treatment, fenbendazole is not that compound either.
Can BPC-157 and Fenbendazole be used together in dogs?+
Combined protocols using both compounds appear in the literature, and they are more often studied together than as alternatives. Any combination increases the difficulty of attributing an adverse effect to a specific compound, so combining should be a deliberate decision made with your veterinarian rather than a default.
Which has better evidence in dogs, BPC-157 or Fenbendazole?+
BPC-157 is graded emerging evidence with 6 cited studies; Fenbendazole is graded emerging evidence with 5 cited studies. Grades reflect the strength of published literature rather than an opinion about efficacy.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.Dogra N, Kumar A, Mukhopadhyay T Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 2018. PMID 30093705
- 8.Song B, et al. Fenbendazole: An Anticancer Agent? A Case Series of Self-Administration. Case Reports in Oncology, 2025. PMC12215191
- 9.CANINE STUDYNguyen J, et al. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research, 2024. View source
- 10.Leach B, et al. Fenbendazole as a Potential Anticancer Drug. Anticancer Research, 2012. PMC3580766
- 11.Kim YJ, et al. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. Current Issues in Molecular Biology, 2023. PMC10670425
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.